TY - JOUR
T1 - Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes
AU - Purrington, Kristen S.
AU - Visscher, Daniel W.
AU - Wang, Chen
AU - Yannoukakos, Drakoulis
AU - Hamann, Ute
AU - Nevanlinna, Heli
AU - Cox, Angela
AU - Giles, Graham G.
AU - Eckel-Passow, Jeanette E.
AU - Lakis, Sotiris
AU - Kotoula, Vassiliki
AU - Fountzilas, George
AU - Kabisch, Maria
AU - Rüdiger, Thomas
AU - Heikkilä, Päivi
AU - Blomqvist, Carl
AU - Cross, Simon S.
AU - Southey, Melissa C.
AU - Olson, Janet E.
AU - Gilbert, Judy
AU - Deming-Halverson, Sandra
AU - Kosma, Veli Matti
AU - Clarke, Christine
AU - Scott, Rodney
AU - Jones, J. Louise
AU - Zheng, Wei
AU - Mannermaa, Arto
AU - Jane Carpenter for ABCTC Investigators, Carpenter for ABCTC Investigators
AU - Eccles, Diana M.
AU - Vachon, Celine M.
AU - Couch, Fergus J.
N1 - Funding Information:
The TNBCC and this tumor study was supported by the Breast Cancer Research Foundation, NIH Grants CA116167, CA192393, and an NIH specialized program of research excellence (SPORE) (P50 CA116201) in breast cancer to Mayo Clinic. K. Purrington completed this work partially as a Mayo Cancer Genetic Epidemiology Training Program (CA92049-03) fellow. The Australian Breast Cancer Tissue Bank is generously supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW, and the National Breast Cancer Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC Grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR). HeCOG research has been co‐financed by the European Union (European Social Fund) and Greek national funds through the operational program Education and Lifelong Learning of the National Strategic Reference Framework Research Funding Program: Thales—investing in knowledge society through the European Social Fund. The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. KBCPstudy was funded by grants from the Finnish Cancer Society, the special Governmental EVO Research Fund of Kuopio University Hospital (grants 53125, 53127, and 53132), and strategic funding of the University of Eastern Finland. SKKDKFZS is supported by the DKFZ. The SBCS was supported by Yorkshire Cancer Research S295, S299, S305PA, and Sheffield Experimental Cancer Medicine Centre. The Nashville Breast Health Study (NBHS) was supported by National Institutes of Health (Grant R01CA100374). POSH is supported by C1275/A11699, C1275/A9896, and C22524.
Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Distinct subtypes of triple negative (TN) breast cancer have been identified by tumor expression profiling. However, little is known about the relationship between histopathologic features of TN tumors, which reflect aspects of both tumor behavior and tumor microenvironment, and molecular TN subtypes. The histopathologic features of TN tumors were assessed by central review and 593 TN tumors were subjected to whole genome expression profiling using the Illumina Whole Genome DASL array. TN molecular subtypes were defined based on gene expression data associated with histopathologic features of TN tumors. Gene expression analysis yielded signatures for four TN subtypes (basal-like, androgen receptor positive, immune, and stromal) consistent with previous studies. Expression analysis also identified genes significantly associated with the 12 histological features of TN tumors. Development of signatures using these markers of histopathological features resulted in six distinct TN subtype signatures, including an additional basal-like and stromal signature. The additional basal-like subtype was distinguished by elevated expression of cell motility and glucose metabolism genes and reduced expression of immune signaling genes, whereas the additional stromal subtype was distinguished by elevated expression of immunomodulatory pathway genes. Histopathologic features that reflect heterogeneity in tumor architecture, cell structure, and tumor microenvironment are related to TN subtype. Accounting for histopathologic features in the development of gene expression signatures, six major subtypes of TN breast cancer were identified.
AB - Distinct subtypes of triple negative (TN) breast cancer have been identified by tumor expression profiling. However, little is known about the relationship between histopathologic features of TN tumors, which reflect aspects of both tumor behavior and tumor microenvironment, and molecular TN subtypes. The histopathologic features of TN tumors were assessed by central review and 593 TN tumors were subjected to whole genome expression profiling using the Illumina Whole Genome DASL array. TN molecular subtypes were defined based on gene expression data associated with histopathologic features of TN tumors. Gene expression analysis yielded signatures for four TN subtypes (basal-like, androgen receptor positive, immune, and stromal) consistent with previous studies. Expression analysis also identified genes significantly associated with the 12 histological features of TN tumors. Development of signatures using these markers of histopathological features resulted in six distinct TN subtype signatures, including an additional basal-like and stromal signature. The additional basal-like subtype was distinguished by elevated expression of cell motility and glucose metabolism genes and reduced expression of immune signaling genes, whereas the additional stromal subtype was distinguished by elevated expression of immunomodulatory pathway genes. Histopathologic features that reflect heterogeneity in tumor architecture, cell structure, and tumor microenvironment are related to TN subtype. Accounting for histopathologic features in the development of gene expression signatures, six major subtypes of TN breast cancer were identified.
KW - Breast cancer
KW - Gene expression
KW - Germline mutation
KW - Pathology
KW - Tumor biology
UR - http://www.scopus.com/inward/record.url?scp=84963760752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963760752&partnerID=8YFLogxK
U2 - 10.1007/s10549-016-3775-2
DO - 10.1007/s10549-016-3775-2
M3 - Article
C2 - 27083182
AN - SCOPUS:84963760752
SN - 0167-6806
VL - 157
SP - 117
EP - 131
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -